CinCor Pharma, Inc. Common Stock
CINC
CINC was delisted on the 23rd of February, 2023.
0 hedge funds and large institutions have $0 invested in CinCor Pharma, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 102 closing their positions.
100% less funds holding
Funds holding: 102 → 0 (-102)
100% less funds holding in top 10
Funds holding in top 10: 4 → 0 (-4)
100% less capital invested
Capital invested by funds: $461M → $0 (-$461M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 102
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$74.6M |
| 2 |
5VM
5AM Venture Management
San Francisco,
California
|
-$60.7M |
| 3 |
GA
General Atlantic
New York
|
-$51.7M |
| 4 |
PA
Perceptive Advisors
New York
|
-$31.7M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$24.5M |
CINC Hedge Fund Activity: Q1 2023 in Review
0 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in CinCor Pharma, Inc. Common Stock (CINC) for Q1 2023, worth a combined $0 — down 100% from $461M a quarter earlier.
Sellers outnumbered buyers: 102 funds closed out of CINC and 0 opened new positions — a net loss of 102 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Sofinnova Investments, exiting entirely with an estimated $74.6M sold.
- 0 institutional investors held CinCor Pharma, Inc. Common Stock (CINC) as of Q1 2023, down from 102 in Q4 2022.
- Funds reported $0 of CinCor Pharma, Inc. Common Stock stock for Q1 2023, down 100% quarter-over-quarter.
- 0 funds opened new CinCor Pharma, Inc. Common Stock positions in Q1 2023 and 102 closed out, a net change of -102 holders.
- The largest CinCor Pharma, Inc. Common Stock seller in Q1 2023 was Sofinnova Investments, an estimated $74.6M sold.
Based on aggregated 13F filings for Q1 2023.